Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.
Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor MD, Chaves M, Suarez R, Paz-Ares L, de la Portilla F, Carranza-Carranza A, Sevilla I, Vicioso L, Garcia-Carbonero R. Molina-Pinelo S, et al. Among authors: vicioso l. BMC Cancer. 2014 Sep 7;14:656. doi: 10.1186/1471-2407-14-656. BMC Cancer. 2014. PMID: 25197016 Free PMC article.
Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Moura DS, Ramos R, Fernandez-Serra A, Serrano T, Cruz J, Alvarez-Alegret R, Ortiz-Duran R, Vicioso L, Gomez-Dorronsoro ML, Garcia Del Muro X, Martinez-Trufero J, Rubio-Casadevall J, Sevilla I, Lainez N, Gutierrez A, Serrano C, Lopez-Alvarez M, Hindi N, Taron M, López-Guerrero JA, Martin-Broto J. Moura DS, et al. Among authors: vicioso l. Oncotarget. 2018 Apr 3;9(25):17576-17588. doi: 10.18632/oncotarget.24799. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707131 Free PMC article.
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Martín M, et al. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505968 Free article. Clinical Trial.
A microRNA signature associated with early recurrence in breast cancer.
Pérez-Rivas LG, Jerez JM, Carmona R, de Luque V, Vicioso L, Claros MG, Viguera E, Pajares B, Sánchez A, Ribelles N, Alba E, Lozano J. Pérez-Rivas LG, et al. Among authors: vicioso l. PLoS One. 2014 Mar 14;9(3):e91884. doi: 10.1371/journal.pone.0091884. eCollection 2014. PLoS One. 2014. PMID: 24632820 Free PMC article.
A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.
Moura DS, Peña-Chilet M, Cordero Varela JA, Alvarez-Alegret R, Agra-Pujol C, Izquierdo F, Ramos R, Ortega-Medina L, Martin-Davila F, Castilla-Ramirez C, Hernandez-Leon CN, Romagosa C, Vaz Salgado MA, Lavernia J, Bagué S, Mayodormo-Aranda E, Vicioso L, Hernández Barceló JE, Rubio-Casadevall J, de Juan A, Fiaño-Valverde MC, Hindi N, Lopez-Alvarez M, Lacerenza S, Dopazo J, Gutierrez A, Alvarez R, Valverde C, Martinez-Trufero J, Martín-Broto J. Moura DS, et al. Among authors: vicioso l. Mol Oncol. 2021 Dec;15(12):3691-3705. doi: 10.1002/1878-0261.12996. Epub 2021 Jun 30. Mol Oncol. 2021. PMID: 33983674 Free PMC article.
Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.
Rueda A, Olmos D, Vicioso L, Quero C, Gallego E, Pajares-Hachero BI, Mendiola M, Casanova M, Álvarez M, Provencio M, Alba E. Rueda A, et al. Among authors: vicioso l. Leuk Lymphoma. 2015 May;56(5):1286-94. doi: 10.3109/10428194.2014.952227. Epub 2015 Feb 7. Leuk Lymphoma. 2015. PMID: 25098430
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo T, Lavado-Valenzuela R, Jimenez B, Pascual T, Gálvez F, Falcón A, Alamo MDC, Morales C, Amerigo M, Pascual J, Sanchez-Muñoz A, González-Guerrero M, Vicioso L, Laborda A, Ortega MV, Perez L, Fernandez-Martinez A, Chic N, Jerez JM, Alvarez M, Prat A, Ribelles N, Alba E. Díaz-Redondo T, et al. Among authors: vicioso l. Front Oncol. 2019 Nov 5;9:1178. doi: 10.3389/fonc.2019.01178. eCollection 2019. Front Oncol. 2019. PMID: 31750258 Free PMC article.
40 results